Two China biotechs drop U.S. IPO plans for $800 million Hong Kong floats: sources

HONG KONG (Reuters) – Two Chinese biotechs have axed plans to list in New York and instead aim to raise up to $800 million in Hong Kong IPOs, seeking to cash in on new rules to woo early-stage drug developers, sources said. Fidelity Investments-backed …
( read original story …)

Related Post